Logo Image
|Videos|February 13, 2017

For Which Infections is Ceftazidime-Avibactam Approved?

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains for which infections ceftazidime-avibactam is approved by the US Food and Drug Administration.

Interview Transcript (slightly modified for readability)

“[Ceftazidime-avibactam] is currently only FDA-approved for intra-abdominal infections and urinary tract infections; however, it seems like a lot of people are using it for a lot of other infections, more severe infections [like] bacteremias [and] pneumonias. I’ve seen posters at these infectious disease conferences [that imply that] people are using it in other infections, and I’ve personally used [ceftazidime-avibactam] in other infections.

So [this combination is] only approved for two infections in the US, but in Europe it’s actually approved for pneumonia, as of, I believe, summer [2016].”

Related to this article

View more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more